Portal de Periódicos da CAPES

Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

2020; Nature Portfolio; Volume: 10; Issue: 1 Linguagem: Inglês

10.1038/s41598-020-66440-9

2045-2322

Rodrigo Jácome, José Alberto Campillo-Balderas, Samuel Ponce de León, Arturo Becerra, Antonio Lazcano,

COVID-19 Clinical Research Studies

As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.